Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
Previous Symbol
CUSIPN/A
Phone617-301-9400
Debt
Debt-to-Equity Ratio0.16
Current Ratio4.11
Quick Ratio3.76
Price-To-Earnings
Trailing P/E Ratio-2.22
Forward P/E Ratio-15.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.87 million
Price / Sales17.90
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.02 per share
Price / Book6.11
Profitability
EPS (Most Recent Fiscal Year)($8.30)
Net Income$-27,010,000.00
Net Margins-88.72%
Return on Equity-52.35%
Return on Assets-36.48%
Miscellaneous
Employees126
Outstanding Shares22,200,000
Market Cap$442.18 million
OptionableNot Optionable
Quanterix (NASDAQ:QTRX) Frequently Asked Questions
What is Quanterix's stock symbol?
Quanterix trades on the NASDAQ under the ticker symbol "QTRX."
How were Quanterix's earnings last quarter?
Quanterix Corp (NASDAQ:QTRX) released its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. The firm earned $10.59 million during the quarter, compared to analyst estimates of $9.57 million. Quanterix had a negative net margin of 88.72% and a negative return on equity of 52.35%. View Quanterix's Earnings History.
When is Quanterix's next earnings date?
What price target have analysts set for QTRX?
5 brokerages have issued twelve-month price targets for Quanterix's shares. Their predictions range from $26.00 to $27.00. On average, they expect Quanterix's stock price to reach $26.6667 in the next twelve months. This suggests a possible upside of 44.6% from the stock's current price. View Analyst Price Targets for Quanterix.
What is the consensus analysts' recommendation for Quanterix?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.
What are Wall Street analysts saying about Quanterix stock?
Here are some recent quotes from research analysts about Quanterix stock:
- 1. Canaccord Genuity analysts commented, "We think investors should own QTRX as it targets growth across 4 phases: 1) expansion in the life sciences research, followed by possible entry into new markets in 2) companion diagnostics; 3) point-of-care diagnostics; and 4) precision health and wellness screening, a $38 billion TAM. We reiterate our BUY rating and $27 PT. Q3 beat. Q3 revenues of $10.6M (+85% Y/Y, +61% adj.) topped our $8.4M (+47%)/ Street’s $8.3M, and included a 1-time payment of $1.3M from its licensing termination with BioMérieux. Product revs of $6.0M (+82% Y/Y) beat our $5.0M, while service revs (ex the 1-timer) of $3.0M was light of our $3.4M. QTRX beat us on consumables (+100% Y/Y beat our +70%) and instruments (+58% Y/Y beat our +30%). ~46% were in line with our 46.5%E. OPEX of $13.3M was above our $10.5ME. Net loss of ($7.7M) exceeded our ($6.9ME)." (11/7/2018)
- 2. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (10/10/2018)
Has Quanterix been receiving favorable news coverage?
News articles about QTRX stock have been trending negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quanterix earned a news impact score of -2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Quanterix's key competitors?
Some companies that are related to Quanterix include Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).
Who are Quanterix's key executives?
Quanterix's management team includes the folowing people:
- Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 57)
- Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 65)
- Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 59)
- Dr. Mark T. Roskey, Sr. VP and GM of Applications & Reagents (Age 58)
- Mr. Joseph S. Driscoll, Chief Financial Officer (Age 53)
When did Quanterix IPO?
(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.
Who are Quanterix's major shareholders?
Quanterix's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (6.00%), Gilder Gagnon Howe & Co. LLC (4.37%), Royce & Associates LP (3.28%), BlackRock Inc. (1.85%), Vanguard Group Inc. (1.56%) and Vanguard Group Inc (1.56%). Company insiders that own Quanterix stock include David R Walt, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.
Which major investors are selling Quanterix stock?
QTRX stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Jennison Associates LLC and JPMorgan Chase & Co.. Company insiders that have sold Quanterix company stock in the last year include E Kevin Hrusovsky, Ernest Orticerio and Joseph Driscoll. View Insider Buying and Selling for Quanterix.
Which major investors are buying Quanterix stock?
QTRX stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., Bellevue Group AG, Point72 Asset Management L.P., Bridgeway Capital Management Inc. and Allianz Asset Management GmbH. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky, John M Connolly and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.
How do I buy shares of Quanterix?
Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quanterix's stock price today?
One share of QTRX stock can currently be purchased for approximately $18.44.
How big of a company is Quanterix?
Quanterix has a market capitalization of $442.18 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe.
What is Quanterix's official website?
How can I contact Quanterix?
Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400.
MarketBeat Community Rating for Quanterix (NASDAQ QTRX)
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
